Good morning, everyone, and thank you for joining us. Since stepping into this role, I've been focused on a singular question: how do we harness the full power of AI to consistently and with urgency ...

Earnings call Recursion Pharmaceuticals delivered strong operational progress with a 30% YoY reduction in operating expenses and an extended cash runway into early 2028. Clinical momentum was ...

Recursion Pharmaceuticals exceeded EPS expectations by 15.38%. The company reported a significant revenue shortfall, missing forecasts by 60.26%. Pre-market stock price fell 1.84% amid broader biotech ...

EPS exceeded forecasts by 15.38%, reflecting effective cost management. Revenue missed expectations by 60.26%, raising concerns about growth prospects. The stock price fell by 5.34% in pre-market ...

Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...

Recursion Pharmaceuticals’ latest earnings call struck a cautiously optimistic tone as management highlighted its first AI-enabled clinical proof-of-concept, major cost cuts, and an extended cash ...

Recursive Superintelligence, founded by former Google, Meta and OpenAI researchers, is part of a growing effort to automate the creation of artificial intelligence. By Cade Metz Reporting from San ...

Blue Owl Capital-owned data center firm Stack Infrastructure is reportedly considering the sale of its Asia operations, in a transaction valued at more than $30 billion. Reporting from Bloomberg, ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

May 6 (Reuters) - Stack Infrastructure, a data centre firm owned by Blue Owl Capital, is considering its options, including a sale of its Asia operations in a deal valued at more ‌than $30 billion, ...